Click on image to view larger version.

Figure 7 Effects of carvedilol versus metoprolol controlled release/extended release (CR/XL) on myocardial substrates, plasma insulin levels, and myocardial glucose uptake in severe dilated cardiomyopathy (DCM). Carvedilol was associated with decreased plasma nonesterified fatty acids (NEFAs) and with increased plasma insulin levels and myocardial glucose uptake compared with metoprolol CR/XL. The indicated p values represent the differences in the carvedilol responses and metoprolol or control responses by analysis of variance. DCM+Rx = DCM plus treatment.